Viromed Medical AG, a medical technology company specializing in cold plasma therapy, has announced new distribution partnerships for its ViroCAP® device in six additional markets, including Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia. The agreements, signed with six separate companies, are expected to generate additional sales of at least 3,000 devices per year, according to a company press release.
ViroCAP® is a mobile medical device designed for treating skin conditions using cold atmospheric plasma, targeting hospitals, private practice physicians, and surgical specialists. The expansion marks a significant step in Viromed’s international growth strategy, which already includes distribution partnerships in Asia and Turkey.
Uwe Perbandt, CEO of Viromed Medical AG, stated, “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology.” He added that additional partnerships for other countries are in preparation and expected to be signed within the next four to six weeks.
The new agreements include minimum purchase quantities, providing Viromed with predictable revenue streams. This strategic move is part of the company’s broader expansion efforts, which have seen it secure exclusive distribution agreements, such as with Korea’s UMECO covering ten Asian countries, and a partnership with TriPart TITAN GmbH & Co. KG for the Turkish market.
The expansion into these markets is significant for several reasons. Firstly, it diversifies Viromed’s revenue base, reducing dependence on its existing DACH region (Germany, Austria, Switzerland) customer base. Secondly, it taps into growing demand for advanced medical technologies in Southern Europe and the Middle East, regions with increasing healthcare investments. Cold plasma therapy is gaining recognition for its antimicrobial and wound-healing properties, making ViroCAP® an attractive option for dermatologists and surgeons.
For the medical community, the availability of ViroCAP® in these new markets could enhance treatment options for patients with chronic skin conditions, potentially improving outcomes and reducing healthcare costs associated with long-term wound care. The device’s portability also makes it suitable for use in diverse clinical settings, from large hospitals to private practices.
Viromed’s aggressive international expansion reflects a broader trend in the medical device industry, where companies are seeking growth opportunities in emerging markets. By securing distribution partnerships, Viromed can leverage local expertise and regulatory knowledge, accelerating market entry and adoption.
The company, listed on the stock exchange since October 2022, aims to further advance cold plasma technology in medicine and realize its growth potential. With these new partnerships, Viromed is well-positioned to increase its global footprint and establish itself as a leader in this niche but rapidly evolving field.
For more information about Viromed Medical AG and its products, visit www.viromed-medical-ag.de.
